February 18, 2026 01:39 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message | India’s wholesale inflation rises to 1.81% in January as manufacturing prices surge | 'India at forefront of AI revolution': PM Modi welcomes world leaders to Delhi summit | Rs 5,000 to women ahead of Tamil Nadu polls! Vijay slams Stalin, says: ‘take the money, blow the whistle’ | Modi congratulates Tarique Rahman as BNP clinches majority in Bangladesh polls | Bangladesh Polls: Tarique Rahman-led BNP secures 'absolute majority' with 151 seats in historic comeback | BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers
COVID19
Pixabay

Portuguese researchers now discover potential drug combo against COVID-19

| @indiablooms | Aug 25, 2021, at 02:34 pm

Lisbon/UNI/Xinhua: A research team in Portugal has found three existing drugs that can help inhibit COVID-19 effects, the Diario de Noticias of Portugal daily reported Tuesday.

During the pre-clinical research, the team from the Institute of Chemical and Biological Technology of NOVA University Lisbon discovered that the drug combination can reduce the replication of SARS-CoV-2, the virus causes COVID-19, by half, said the report.

"With the drugs, we had identified that the virus only replicated at 50 percent," said Cecilia Arraiano, who leads the team, noting that the synergy could act on the Nsp14, a viral protein responsible for replication, to dampen virus activity.

The drugs could be a potential treatment that helps reduce COVID-19 hospitalization rate, according to the team.

Two of the drugs are over-the-counter medicines for treating other diseases, and the third one is pending market approval, researchers said, without disclosing drug names due to patent concern.

Arraiano said it took them nine months to have a pre-clinical discovery, and now she hopes to have more financial support to push it forward.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.